Latest News

Sarah Poland, MD, discussed the divergence between the IMpassion130 and IMpassion131 trials and the critical role of confirmatory trials in oncology.

Data from RETAIN-1 and RETAIN-2 show the chemoradiotherapy or BCG may remain viable options in those with ctDNA negativity but evidence of local disease.

Phase 3 data support perioperative enfortumab vedotin plus pembrolizumab as a novel treatment option in MIBC regardless of eligibility for cisplatin.

The expansion of clinical trials evaluating proton-based radiotherapy could elucidate its benefits and increase its access across the US.

Retrospective data show that relapse-free survival outcomes were worse for patients with MDS/MPN compared with those who had other types of MDS.

Often, patients in middle-income settings, are the patients who are impacted most by insurance deductibles, according to Loretta Nastoupil, MD.

Relacorilant plus nab-paclitaxel improved PFS among patients with PROC who had progression after a PARP inhibitor or who were 65 years or older.

Explore the latest clinical data and therapeutic strategies for acral, mucosal, and uveal melanomas from Mark B. Faries, MD, FACS.

Results from the PEACE-3 trial found an extended OS after patients with metastatic castration-resistant prostate cancer were treated with enzalutamide/radium-223.

Data from the CAPItello-281 trial may support capivasertib/abiraterone as a first-in-class targeted therapy in this metastatic hormone-sensitive prostate cancer population.

Yan Leyfman, MD, reviewed how toxicity management in hematologic oncology is shifting to phenotype- and mechanism-informed intervention.

Data from the phase 2 BRCAAway trial showed the longest survival with olaparib plus abiraterone/prednisone vs each agent given alone or sequentially.

Loretta Nastoupil, MD, reflected on some of the differences between practicing in a rural, community cancer center compared with a larger institutional center.

The FDA approved zongertinib in HER2-mutated NSCLC as part of its Commissioner's National Priority Voucher pilot program.

Development of the oral DHX9 inhibitor, ATX-559, has been halted following adverse events in a phase 1/2 trial of patients with metastatic solid tumors.

The EGFR/HER3 bispecific ADC met the primary end points of PFS and OS in patients with advanced triple-negative breast cancer.

Experts review potential clinical advances highlighted at the 2026 ASCO Gastrointestinal Cancers Symposium.

Preliminary findings have shown an “unprecedented” result with blinatumomab in mixed phenotype acute leukemia, according to Ashkan Emadi, MD, PhD.

Sarah Poland, MD, discussed the transition of breast cancer from an "immunologically cold" tumor to a target for checkpoint inhibitors, highlighting the pivotal role of the KEYNOTE-012 trial.

Irtiza Sheikh, DO, sought to assess the impact of age and clinical setting on liso-cel efficacy in patients with large B-cell lymphoma.

The willingness-to-pay metric is a tool that varies by individual country, which is used to determine how much a patient might pay for their treatment.

A partial clinical hold has been placed on the phase 2 LINNET trial following the report of several serious safety events, including 1 treatment-related death.

James Larkin, MD, PhD, highlighted toxicities associated with immune checkpoint inhibitors in melanoma at a recent Physicians Education Resource meeting.

SRN-101, an AAV-based immuno-gene therapy, has received fast track designation for the treatment of recurrent high-grade glioma.

Hematologic adverse effects with KTX-1001 among patients with relapsed/refractory multiple myeloma were “very well expected” in a phase 1 trial.

Jason Molitoris, MD, PhD, discussed 2025 data on proton therapy for oropharyngeal cancer, highlighting immune preservation and reduced long-term AEs.

Discover how PSMA PET sharpens staging, guides radioligand therapy sequencing, and tackles real‑world access hurdles in advanced prostate cancer.

Based on the ability for select TILs to confer antitumor activity, Mauro Cives, MD, began his research assessing TCR-based therapies in pancreatic NETs.

Though durvalumab was priced higher than most willingness-to-pay thresholds, an initiative out of Singapore demonstrated that difference can be managed.

Results from the BREAKWATER trial led to the traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy in BRAF-mutated CRC.

First-line nivolumab plus chemotherapy provides a durable survival benefit in advanced gastric cancers, particularly in patients with a PD-L1 CPS of 5 or higher.